At Fortrea, our mission is clear. We aim to be the CRO of choice for clinical trial sites. We’re leading the way in transforming the landscape of clinical research by listening, collaborating and responding to the needs to sites, leaving them free to do what sites do best – patient care.
We've launched Fortrea Site Connections to coordinate these efforts, actively listening to the needs of sites, understanding more deeply the practical realities of diverse patients wherever they are, and aiding the development of protocols that can be done, and protocols that patients want to do.
Read more on our website
Whitepaper: Fortrea Site Connections: promoting collaborative partnerships between sites and CROs
Sites represent both the front line and the last mile of a clinical trial, underlining the essential role they play in making clinical trials a reality for the patients in their care. It stands to reason, therefore, that by focusing on removing the roadblocks and challenges faced by sites and patients, more cutting-edge treatments will reach more patients sooner. Building on our 30+ years of experience as a CRO and our agility as a newly independent entity, we have established Fortrea Site Connections to coordinate our site-focused efforts. Learn how we’re proactively engaging sites, actively listening to their needs and responding with innovative new approaches that seek to truly enable sites to do what sites do best: deliver trials to the patients in their care.
Video: Empowering voices
Fortrea established the Site Advisory Board as a mechanism to listen more intently to the needs and perspectives of sites, not only the challenges but also the opportunities to innovate and be bold. Our Site Advisory Board membership is growing globally as we give a voice to sites and investigators who are working every day to deliver clinical trials to the people who need them most – patients.
Infosheet: Reimagining site activation with ready to enroll (RTE) goals
Preparing investigator sites sets the foundation for strong patient recruitment in clinical trials. When you need to get your sites up and running fast, our site readiness team can provide oversight support in every stage, from site identification to finalization and handover.
Video: The right site for your study
Data – and the way that we can process those data – is key to Fortrea’s ability to enroll the right sites for your studies. Sites that are ready, capable, passionate and serving the communities we need to reach. Fortrea is innovating in how we process those data, applying AI algorithms to predict performance. Together this means faster start up and better data quality.
Whitepaper: Cardiometabolic rare diseases: Strategic insights for country and site distribution
Clinical plan strategies in traditional indications typically incorporate regulatory considerations, cost, investigator access and an assessment of the competitive and reimbursement landscape, but the strategies for rare disease trials are more complex. To help drug development sponsors run efficient cardio-metabolic rare disease studies, this white paper shares key operational considerations and describes the use of proprietary tools and processes combined with information in the public domain to support both country and site selection.
Video: Reducing complexity in clinical trial delivery
Video: A better clinical trial experience
Our north star is our patients. Creating a better clinical trial experience is at the heart of how we design and deliver studies, removing obstacles to enable sites to do what sites do best – patient care. We deliver positive patient experiences, by directly listening to patients and advocacy groups –resulting in faster recruitment, improved adherence and greater study retention.
Whitepaper: Promoting patient and site centricity in neurodegenerative disease clinical trials
Whitepaper: The importance of early investment in patient engagement
Enabling sites to do what sites do best
Fortrea places sites and investigators at the forefront of trial planning and operations, working together to strengthen trial delivery and expand healthcare options for all.
